Full Press Release Details
Liminatus Pharma Announces Compliance with Nasdaq
PALMA, Calif., June 4, 2025 - Liminatus Pharma, Inc. (Nasdaq: LIMN) ("Liminatus" or the "Company"),
a pre-clinical stage biopharmaceutical company developing novel, immune-modulating cancer therapies, today announced that on June 3, 2025,
it received a notification letter from Nasdaq indicating that it now complies with Nasdaq Listing Rule 5250(c)(1) which requires timely
filing of reports with the U.S. Securities and Exchange Commission and the matter is now closed.
Prior to its filing on June 2, 2025, the Company
had received a notification letter from Nasdaq on May 29, 2025, stating that the Company was not in compliance with Nasdaq Listing Rule
5250(c)(1) as a result of the delay in filing its Quarterly Report on Form 10-Q for the period ended March 31, 2025. On June 2, 2025,
the Company filed the Form 10-Q such that it is now current with respect to its Exchange Act reporting obligations.
Liminatus Pharma, Inc. is pre-clinical stage biopharmaceutical
company developing novel, immune-modulating cancer therapies. The Company's candidate IBA101, is a humanized anti CD47 monoclonal
antibody. The next generation CD47 checkpoint inhibitor's initial indication is expected to be patients with advanced solid cancers
including non-small cell lung cancer. The Company's vision is to develop a broad array of transformative therapies for cancer patients
as a leading global biopharmaceutical company.
For more information, please contact: